| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
90,436 |
85,456 |
$5.68M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
93,955 |
89,313 |
$2.97M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
28,154 |
25,533 |
$2.44M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40,699 |
38,709 |
$1.72M |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
123,177 |
58,424 |
$1.16M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
18,071 |
16,289 |
$1.04M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
51,637 |
49,497 |
$489K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
3,754 |
3,587 |
$376K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
7,200 |
6,590 |
$341K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,148 |
1,949 |
$92K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,238 |
1,176 |
$32K |
| 99215 |
Prolong outpt/office vis |
255 |
239 |
$21K |
| 99205 |
Prolong outpt/office vis |
159 |
157 |
$19K |
| 87428 |
|
313 |
255 |
$14K |
| 87807 |
|
1,491 |
1,463 |
$12K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
761 |
648 |
$9K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
415 |
390 |
$5K |
| 81003 |
|
3,429 |
3,254 |
$5K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
20 |
19 |
$2K |
| 0012A |
|
47 |
38 |
$2K |
| 0011A |
|
43 |
38 |
$2K |
| 81002 |
|
666 |
631 |
$1K |
| 81025 |
|
142 |
138 |
$706.15 |
| 86308 |
|
127 |
127 |
$359.34 |
| 99201 |
|
13 |
13 |
$351.00 |
| 71046 |
Radiologic examination, chest; 2 views |
17 |
17 |
$222.36 |
| 99051 |
|
13 |
13 |
$124.80 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
101 |
85 |
$105.54 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
43 |
42 |
$66.16 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
21 |
15 |
$19.45 |
| 99000 |
|
10,930 |
9,575 |
$3.68 |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
259 |
235 |
$0.00 |